Skip to content

The pipeline for HIV prevention products holds the potential to curb HIV incidence. But we know from previous products that translating trial efficacy to population impact is challenging without coordinated effort. The Biomedical Prevention Implementation Collaborative is pioneering an innovative, integrated and adaptable approach to product introduction, with a focus on injectable cabotegravir (CAB) for PrEP.

BioPIC developed the Adaptable Product Introduction Framework for all stakeholders involved in product introduction, from clinical research to rollout in low- and middle-income countries. The framework prioritizes activities that must begin in parallel to phase III clinical trials. Stakeholders with a role in early phase product development may also benefit from these considerations with better coordination around anticipated needs.


Think Tanks

An ongoing series of think tanks, conducted by BioPIC, are generating key insights for people-centered product delivery. Visit Events for information on upcoming think tanks.

Previous Think Tanks:

Generating Demand for HIV Biomedical Prevention in the Era of Choice
June 2022
In light of the emerging need to (re-)define how to generate demand for choice in HIV biomedical prevention, AVAC, under BioPIC, convened program implementers; social and behavioural change communication, marketing, and design thinking experts; behavioral economists; researchers; donors; and civil society to identify proven and promising strategies and models to more effectively reach and engage different populations. Nine experts/organizations drawn from both the HIV and family planning sectors shared insights from their previous and current demand generation interventions for different populations and geographical contexts.
Learn more.

Coordinating Implementation Science for CAB for PrEP
April 2022
As implementation studies for injectable CAB for PrEP are being considered and as programs shift towards choice-based models for HIV prevention, there is a chance to correct for missed opportunities with oral PrEP rollout, understand client preferences and patterns of use, and ensure more effective coordination across geographies, populations, and projects. To facilitate this coordination, AVAC and WHO convened implementers, donors, members of civil society organisations, and the developer of CAB for PrEP to share plans for implementation studies.
Learn more.

Modelling the Impact of Injectable CAB for PrEP on Drug Resistance
April 2022
An important consideration in the scale-up of injectable CAB for PrEP is the potential for development of Integrase Strand Transfer Inhibitor (INSTI) resistance. To help stakeholders understand this issue further, Professor Andrew Phillips from University College London shared the results of an exercise modelling the impact of the introduction of CAB for PrEP on INSTI resistance and AIDS-related mortality, as well as cost-effectiveness.
Learn more.

HIV Testing and Injectable CAB for PrEP Introduction: What are the implications for HIV prevention scale-up and the HIV response?
December 2021
One challenge which has emerged with the introduction of CAB for PrEP is the risk of INSTI resistance amongst people who acquire HIV while taking CAB as prescribed. To address emerging evidence around testing algorithms and INSTI resistance in CAB users, AVAC and WHO convened a think tank with program implementers, testing experts, mathematical modelers, policy makers, donors, and civil society.
Learn more.

Product Introduction/Implementation Project Planning for Next-Generation PrEP
September 2021
Early data from clinical trials has indicated that CAB for PrEP is safe and effective. With an accelerated timeline for introduction of CAB for PrEP, AVAC and WHO convened a think tank to strategize about demonstration projects and other planning for product introduction.
Learn more.